GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Odyssey Group International Inc (OTCPK:ODYY) » Definitions » ROE %

Odyssey Group International (Odyssey Group International) ROE % : 4,332.14% (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Odyssey Group International ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Odyssey Group International's annualized net income for the quarter that ended in Jan. 2024 was $53.11 Mil. Odyssey Group International's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was $1.23 Mil. Therefore, Odyssey Group International's annualized ROE % for the quarter that ended in Jan. 2024 was 4,332.14%.

The historical rank and industry rank for Odyssey Group International's ROE % or its related term are showing as below:

ODYY' s ROE % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: Negative Equity

ODYY's ROE % is ranked better than
99.88% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.125 vs ODYY: Negative Equity

Odyssey Group International ROE % Historical Data

The historical data trend for Odyssey Group International's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odyssey Group International ROE % Chart

Odyssey Group International Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
ROE %
Get a 7-Day Free Trial Premium Member Only - - - - -

Odyssey Group International Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 4,332.14

Competitive Comparison of Odyssey Group International's ROE %

For the Medical Devices subindustry, Odyssey Group International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Odyssey Group International's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Odyssey Group International's ROE % distribution charts can be found below:

* The bar in red indicates where Odyssey Group International's ROE % falls into.



Odyssey Group International ROE % Calculation

Odyssey Group International's annualized ROE % for the fiscal year that ended in Jul. 2023 is calculated as

ROE %=Net Income (A: Jul. 2023 )/( (Total Stockholders Equity (A: Jul. 2022 )+Total Stockholders Equity (A: Jul. 2023 ))/ count )
=-5.919/( (-4.644+-6.156)/ 2 )
=-5.919/-5.4
=N/A %

Odyssey Group International's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=53.112/( (-6.218+8.67)/ 2 )
=53.112/1.226
=4,332.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


Odyssey Group International  (OTCPK:ODYY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=53.112/1.226
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(53.112 / 0)*(0 / 7.331)*(7.331 / 1.226)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*5.9796
=ROA %*Equity Multiplier
=N/A %*5.9796
=4,332.14 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=53.112/1.226
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (53.112 / 53.112) * (53.112 / -4.628) * (-4.628 / 0) * (0 / 7.331) * (7.331 / 1.226)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -11.4762 * N/A % * 0 * 5.9796
=4,332.14 %

Note: The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Odyssey Group International ROE % Related Terms

Thank you for viewing the detailed overview of Odyssey Group International's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Odyssey Group International (Odyssey Group International) Business Description

Traded in Other Exchanges
N/A
Address
2300 West Sahara Avenue, Suite 800 - No. 4012, Las Vegas, NV, USA, 89102
Odyssey Group International Inc is a company focused on developing life-saving medical products, Odyssey's goal is to create, acquire and accumulate distinct assets, intellectual property, and technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.
Executives
Erik C. Emerson other: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Gregory W Gironda other: Chief Operating Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Ricky Richardson director 2372 MORSE AVE., IRVINE CA 92614
Christine Farrell officer: Controller/Secretary 2372 MORSE AVE, IRVINE CA 92614
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Jerome H Casey director 2372 MORSE AVE, IRVINE CA 92614
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Vanlandingham Jacob Ph.d director 2372 MORSE AVE, IRVINE CA 92614
J Michael Redmond director, officer: President/CEO 10 CANTERBURY ROAD, WINDHAM NH 03087